APOE4-microglial complement signaling causes cholinergic-enriched synaptic vuln…

Mechanistic description

APOE4 may bias microglia toward complement-mediated pruning that disproportionately strips vulnerable long-range cholinergic synapses, lowering acetylcholine tone and facilitating tau spread. The debate supports this as a strong modifier or subtype mechanism, but the claim of cholinergic selectivity remains underproven.

Mechanism / pathway

APOE, C1QA, C1QB, C1QC, C3, ITGAM
→
neurodegeneration

Evidence for (7)

APOE4 strongly shapes early AD biology, and complement-mediated synapse loss is a well-supported mechanism in AD.
Cholinergic-system biomarkers such as FEOBV PET enable direct testing of cholinergic enrichment in human cohorts.

PMID:28894304
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.

PMID:33340485 2021 Lancet Neurol
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies.

PMID:31367008 2019 Nat Rev Neurol
APOE deficiency inhibits amyloid-facilitated (A) tau pathology (T) and neurodegeneration (N), halting progressive ATN pathology in a preclinical model.

PMID:40307424 2025 Mol Psychiatry
Associations Between APOE Variants, Tau and α-Synuclein.

PMID:32096038 2019 Adv Exp Med Biol
Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes.

PMID:39532095 2025 Cell

Evidence against (2)

Selective targeting of cholinergic synapses is inferred more than demonstrated; APOE4 may instead act through broader lipid, vascular, or amyloid-clearance pathways.
Clinical microglial-targeting programs have shown target engagement without efficacy and can carry inflammatory or ARIA-like liabilities.

Evidence matrix

7 supporting 2 contradicting

55% posterior support

Supporting

APOE4 strongly shapes early AD biology, and complement-mediated synapse loss is a well-supported mechanism in AD.
Cholinergic-system biomarkers such as FEOBV PET enable direct testing of cholinergic enrichment in human cohorts. PMID:28894304
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. PMID:33340485 · 2021 · Lancet Neurol
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. PMID:31367008 · 2019 · Nat Rev Neurol
APOE deficiency inhibits amyloid-facilitated (A) tau pathology (T) and neurodegeneration (N), halting progressive ATN pathology in a preclinical model. PMID:40307424 · 2025 · Mol Psychiatry
Associations Between APOE Variants, Tau and α-Synuclein. PMID:32096038 · 2019 · Adv Exp Med Biol
Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes. PMID:39532095 · 2025 · Cell

Contradicting

Selective targeting of cholinergic synapses is inferred more than demonstrated; APOE4 may instead act through broader lipid, vascular, or amyloid-clearance pathways.
Clinical microglial-targeting programs have shown target engagement without efficacy and can carry inflammatory or ARIA-like liabilities.

Bayesian persona consensus

55% posterior support

1 signal · 1 for / 0 against · agreement 100%

scidex.consensus.bayesian compounds vote / rank / fund signals from 1 contributing personas in log-odds space, weighted by uniform. Prior 50%.

Cite this hypothesis

Citation

etl-backfill (2026). APOE4-microglial complement signaling causes cholinergic-enriched synaptic vuln…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-ff7cdd9b05

BibTeX

@misc{scidex_hypothesis_hff7cdd9,
  title        = {APOE4-microglial complement signaling causes cholinergic-enriched synaptic vuln…},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-ff7cdd9b05},
  note         = {SciDEX artifact hypothesis:h-ff7cdd9b05}
}